Free Trial
→ INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off (From Traders Agency) (Ad)tc pixel Free CLPBY Stock Alerts

Coloplast A/S (CLPBY) Stock Forecast & Price Target

Coloplast A/S logo
$8.59 +0.05 (+0.59%)
As of 09/26/2025 04:00 PM Eastern
Compare

Coloplast A/S - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 5 Analyst Ratings
Sell
0
Hold
4
Buy
1

Based on 5 Wall Street analysts who have issued ratings for Coloplast A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 4 have given a hold rating, and 1 has given a strong buy rating for CLPBY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CLPBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coloplast A/S and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLPBY Analyst Ratings Over Time

TypeCurrent Forecast
9/27/24 to 9/27/25		1 Month Ago
8/28/24 to 8/28/25		3 Months Ago
6/29/24 to 6/29/25		1 Year Ago
9/28/23 to 9/27/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
 N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldHoldHoldN/A

CLPBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CLPBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Coloplast A/S Stock vs. The Competition

TypeColoplast A/SMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted UpsideN/A2,768.07% Upside11.54% Upside
News Sentiment Rating
Neutral News

See Recent CLPBY News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
5/9/2025Royal Bank Of Canada
4 of 5 stars
J. Reynolds-Clar
Not Rated
DowngradeModerate Buy ➝ Hold
5/7/2025Barclays
3 of 5 stars
H. Al-Wakeel
Not Rated
DowngradeStrong-Buy ➝ Hold
1/28/2025Sanford C. Bernstein
3 of 5 stars
L. Clive
Not Rated
UpgradeHold ➝ Strong-Buy
12/11/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
G. Doyle
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
11/18/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
S. Gupta
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeModerate Sell ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:01 AM ET.


Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 24, 2025. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Coloplast A/S:

  • The company has recently updated its earnings guidance for FY 2025, indicating a revenue forecast of approximately $4.2 billion to $4.4 billion, which aligns with market expectations and suggests stable growth.
  • Coloplast A/S offers a diverse range of innovative healthcare products, including the latest versions of ostomy care solutions like SenSura Mio, which are designed for optimal discretion and fit, appealing to a broad customer base.
  • The current stock price is around $20, reflecting a stable position in the market, which may attract investors looking for reliable investment opportunities in the healthcare sector.
  • The company operates in multiple segments, including Chronic Care and Advanced Wound Care, which helps mitigate risks associated with reliance on a single product line, providing a balanced revenue stream.
  • Coloplast A/S has a strong international presence, with operations in key markets such as the United States and the United Kingdom, enhancing its growth potential and market reach.

Coloplast A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Coloplast A/S for these reasons:

  • The company’s revenue guidance of $4.2 billion to $4.4 billion is at the lower end of market expectations, which may indicate potential challenges in meeting growth targets.
  • Coloplast A/S operates in a highly competitive industry, with numerous players in the medical instruments sector, which could pressure margins and market share.
  • Recent fluctuations in stock price may raise concerns about market volatility, which can affect investor confidence and long-term investment stability.
  • As the company continues to innovate, there is always a risk associated with the development and acceptance of new products in the market, which could impact future sales.
  • Economic uncertainties and regulatory changes in key markets could pose risks to Coloplast A/S's operations and profitability, making it a less attractive investment in the current climate.

CLPBY Forecast - Frequently Asked Questions

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There are currently 4 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CLPBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.

According to analysts, Coloplast A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Analysts like Coloplast A/S less than other "medical" companies. The consensus rating for Coloplast A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CLPBY compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (OTCMKTS:CLPBY) was last updated on 9/27/2025 by MarketBeat.com Staff
From Our Partners
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...
Investors Alley | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsoredtc pixel
Crypto Gets Official Government Backing—Here's the Winner
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...
Crypto 101 Media | Sponsoredtc pixel
Warren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the Nasdaq
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...
Altimetry | Sponsoredtc pixel